Bristol-Myers Squibb (BMY) Tops Q2 EPS by 40c; raises guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $66.82 -1.87%
EPS Growth %: +5.5%
Financial Fact:
Total Expenses: 3.36B
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: +5.5%
Financial Fact:
Total Expenses: 3.36B
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.46, $0.40 better than the analyst estimate of $1.06. Revenue for the quarter came in at $12.27 billion versus the consensus estimate of $11.34 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2025 EPS of $6.35-$6.65, versus the consensus of $6.32. Bristol-Myers Squibb sees FY2025 revenue of $46.5-47.5 billion, versus the consensus of $46.265 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- ADARx Pharmaceuticals files for proposed IPO
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
